Figure 6. Flow of target discovery and drug development based on recent genetic studies. Progress and cost reduction in genetic analysis and bioinformatics helped the identification of rare functional variants that would have been previously impossible. Improvement in production of gene-targeting therapeutics improved the success rate in drug development.

Ab = antibody; ASO = antisense oligonucleotide; CV = cardiovascular; LOF = loss-of-function..